Chemical compound ETH-LAD, or ETHLAD, also known as 6-ethyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD; also known as METH-LAD). It is slightly more potent than LSD and is among the most potent psychedelics known. The drug is taken orally. I

How long does ETH-LAD last?

The total duration of ETH-LAD via oral is 8 hours to 12 hours. Onset typically occurs within 20 minutes to 40 minutes. Peak effects last 4 hours to 6 hours.

ETH-LAD — SubstanceWiki

SubstanceWiki

⌘K

How It Feels

The body knows first. Before any visual signature appears, there is a spreading heaviness in the abdomen, a tightness that wraps around the stomach and reaches into the lower back. ETH-LAD has a pronounced physical presence that announces itself within the first twenty minutes. Nausea is common, not always severe but persistent enough to color the early experience with a quality of endurance. The muscles tighten and a buzzing, electric tension settles into the limbs, as though the body has been plugged into a low-voltage current.

Then the visuals arrive, and they arrive with authority. ETH-LAD is among the most visually intense substances in the lysergamide family. Surfaces do not merely breathe; they shatter into crystalline geometries, fracture and reassemble, pulse with impossible colors. The visual field takes on a sharpened, almost hyper-defined quality, and closed-eye imagery is dense and elaborate, towering structures of light and pattern that rotate and evolve with mechanical precision. The contrast between the visual magnificence and the physical discomfort creates a tension that is central to the ETH-LAD experience.

The headspace is genuinely confusing. Thoughts fragment and recombine in unexpected ways. Linear reasoning becomes difficult, and there is a quality of cognitive slipperiness that can be profoundly disorienting. Time perception is severely distorted, minutes stretch into what feel like hours, and there are moments where time seems to fold back on itself. Emotional responses are intense and rapid, shifting from awe to anxiety to hilarity with little transition. At higher doses the boundaries of self can become uncertain, though this dissolution has a different character from tryptamine ego loss, it is more angular, more crystalline, less oceanic.

The shorter duration is a mercy. By five to six hours the peak has clearly broken, and the gradual return to baseline is accompanied by a slow release of physical tension. The stomach settles, the muscles unclench, and the visual intensity softens into gentle patterning. The afterglow often carries a quality of exhausted wonder, the feeling of having been shown something extraordinary through a window that was uncomfortable to look through. There may be residual muscle soreness and a desire for rest. Sleep, when it comes, tends to be deep.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(15)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Excessive yawning— Involuntary, repeated yawning that occurs far more frequently than normal and often without the usua...
Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Watery eyes— Excessive tear production causing overflow tearing and blurred vision, commonly occurring during opi...

Cognitive & Perceptual Effects

Visual(16)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...

Pharmacology

As with LSD and other compounds in the lysergamide family, ETH-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from ETH-LAD's efficacy at the 5-HT2A receptors, although it is likely that like LSD, ETH-LAD also binds to a wide range of different receptors, including multiple different subtypes of serotonin receptors as well as dopamine and adrenoreceptors well.

However, the role of these interactions and how they result in the psychedelic experience remains subject to on-going scientific investigation.

While the subjective effects of ETH-LAD are reported to largely overlap with those of LSD, it has been noted for the tendency to be more visually and auditorily distortive, introspective, analytical and immersive yet with the capacity to produce pronounced discomforting physical effects like severe and persisting nausea, and temperature dysregulation past the common dose range in a seemingly unpredictable manner.

Due to its high potency and sensitive dose-response, many reports also indicate that the effects of this substance may be overly intense for those who are not already very experienced with psychedelics. Users are advised to approach this substance with caution, use a full array of harm reduction practices, and pay close attention to their physical conditions and environment if using this substance.

The toxicity and long-term health effects of recreational ETH-toxic dose is unknown. This is because ETH-LAD is a research chemical with very little history of human usage.

Anecdotal reports from those who have tried ETH-LAD suggests that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (although nothing can be guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

ETH-not habit-forming and the desire to use it can actually decrease with use. As with most psychedelics, it is generally considered to have a built-in, self-regulating aspect to it, although cases of its abuse have been reported.

Tolerance to the effects of ETH-almost immediately after ingestion. After that,5-714 days to return to baseline (in the absence of further consumption). ETH-LAD presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of ETH-LAD all psychedelics will display a reduced effect.

Overdose

While ETH-LAD has no known toxic dosage, many anecdotal reports suggest this compound to be harsher to handle in overdoses when compared to LSD or other lysergamides. Overdose effects can already start in the heavy dose range and are described as being particularly uncomfortable and bizarre. Some of these effects include anxiety, delusions, confusion, panic attacks, severe nausea and body load, and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects.

ETH-LAD is currently a gray area compound within many parts of the world. This means that it is not known to be specifically illegal within most countries. People may still be charged for its possession under certain circumstances such as under analogue laws (as an analogue of LSD) and with the intent to sell or consume.

Austria: ETH-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Germany: ETH-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Latvia: ETH-LAD is illegal in Latvia. Although ETH-LAD is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Poland: ETH-LAD is a NPS class drug in Poland, making it illegal to possess or distribute.
Switzerland: ETH-LAD is a controlled substance specifically named under Verzeichnis E.. It is scheduled as of the of December 1, 2015.
Turkey:** ETH-LAD is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: As of January 7, 2015, ETH-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A controlled substance.
United States: ETH-LAD is unscheduled in the United States. It may be considered an analogue of LSD (which is a Schedule I compound under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or scientific research could be prosecuted as crimes under the Federal Analogue Act.
Responsible use (Hallucinogens)
Research chemical
Psychedelic
Lysergamide
AL-LAD
PRO-LAD
LSD
ETH-LAD (Wikipedia)
ETH-LAD (TiHKAL / Isomer Design)
Discussion
The Big & Dandy ETH-LAD Thread (Bluelight)
Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.

Detection Methods

Urine Detection

ETH-LAD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.

Blood and Serum Detection

Blood detection windows for ETH-LAD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.

Standard Drug Panel Inclusion

ETH-LAD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.

Confirmatory Methods

When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.

Reagent Testing (Harm Reduction)

For harm reduction identification, the Ehrlich reagent is the primary tool for ETH-LAD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens The toxicity and long-term health effects of recreational ETH-LAD use in humans does not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because ETH-LAD is a research chemical with very little history of human usage.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

ETH-LAD is not habit-forming and the desire to use it can actually decrease with use. As with most psychedelics, it is generally considered to have a built-in, self-regulating aspect to it, although cases of its abuse have been reported.

Tolerance to the effects of ETH-LAD builds almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to return to baseline (in the absence of further consumption). ETH-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of ETH-LAD all psychedelics will display a reduced effect.

Overdose

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Lithium - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
Cannabis - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of ETH-LAD. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
Stimulants - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.
Tramadol - Tramadol is well-documented to lower the seizure threshold and psychedelics may act to trigger seizures in susceptible individuals.

Addiction Potential

not habit-forming

Overdose Information

Overdose

Austria: ETH-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Germany: ETH-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Latvia: ETH-LAD is illegal in Latvia. Although ETH-LAD is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Poland: ETH-LAD is a NPS class drug in Poland, making it illegal to possess or distribute.
Switzerland: ETH-LAD is a controlled substance specifically named under Verzeichnis E.. It is scheduled as of the of December 1, 2015.
Turkey:** ETH-LAD is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: As of January 7, 2015, ETH-LAD is s

Legal Status

Austria: ETH-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
Germany: ETH-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Latvia: ETH-LAD is illegal in Latvia. Although ETH-LAD is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
Poland: ETH-LAD is a NPS class drug in Poland, making it illegal to possess or distribute.
Switzerland: ETH-LAD is a controlled substance specifically named under Verzeichnis E.. It is scheduled as of the of December 1, 2015.
Turkey:** ETH-LAD is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: As of January 7, 2015, ETH-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A controlled substance.
United States: ETH-LAD is unscheduled in the United States. It may be considered an analogue of LSD (which is a Schedule I compound under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or scientific research could be prosecuted as crimes under the Federal Analogue Act.
Responsible use (Hallucinogens)
Research chemical
Psychedelic
Lysergamide
AL-LAD
PRO-LAD
LSD
ETH-LAD (Wikipedia)
ETH-LAD (TiHKAL / Isomer Design)
Discussion
The Big & Dandy ETH-LAD Thread (Bluelight)
Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.

Cognitive(21)

Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
Multiple thought streams— The experience of having more than one internal narrative or stream of consciousness simultaneously ...
Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
Thought organization— Enhanced ability to structure, categorize, and systematize thoughts and ideas, common with low-dose ...
Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...

ETH-LAD

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(15)

Cognitive & Perceptual Effects

Visual(16)

Pharmacology

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Harm Reduction

Toxicity & Safety

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (13)

Community Discussions (5)

See Also

Similar by Effects

Same Class

References (6)

Frequently Asked Questions

Cognitive(21)

Auditory(3)

Multi-sensory(1)

Transpersonal(4)

Full	almost immediately after ingestion
Half	5-7 days
Zero	14 days